FDA Approves Drug Combo for Kidney Cancer.
The FDA has approved the combination of lenvatinib and everolimus to treat advanced or metastatic renal cell carcinoma. The approval marks the first time that tyrosine kinase and mTOR inhibitors have been combined successfully as second-line treatment for renal cell carcinoma following prior VEGF-targeted therapy.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D000068338:Everolimus / Q000008:administration & dosage; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D010671:Phenylurea Compounds / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011804:Quinolines / Q000008:administration & dosage; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011804:Quinolines; D000068338:Everolimus; C531958:lenvatinib